^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:DZD1516 (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

    Excerpt:
    ...- histologically or cytologically confirmed HER2 positive advanced breast cancer which failed prior therapies...
    Trial ID:
    NCT04509596
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res
    Title:

    Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

    Published date:
    07/06/2023
    Excerpt:
    Phase 1 clinical study of DZD1516 in patients with HER2+ metastatic breast cancer...With median seven lines of prior systemic treatment, per investigators’ assessment, the best antitumor efficacy in intracranial, extracranial, and overall lesions were stable disease...A total of 6 out of 23 patients achieved stable disease.
    DOI:
    10.1186/s13058-023-01679-4